Checkpoint Therapeutics reports Q1 EPS (33c), consensus (10c)

Reports Q1 revenue $0, consensus $10,000. As of March 31 Checkpoint’s cash and cash equivalents totaled $11.2M, compared to $4.9M at December 31, 2023, an increase of $6.3M. James Oliviero, President and CEO of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization for cosibelimab to resolve their inspection deficiencies noted in the complete response letter we received from the FDA last December. Recently, our CMO submitted to FDA their response to the inspection deficiencies, which we believe could allow for the resubmission of our biologics license application. We plan to meet with the FDA shortly, at which time we will seek to reach alignment for a potential mid-year BLA resubmission.”